Zydus Lifesciences on Saturday said it has received approval from the U.S. health regulator to market a generic anti-epileptic medication.
The company has received approval from the U.S. Food and Drug Administration to manufacture and market Lacosamide Tablets in multiple strengths, the drug firm said in a statement.
Lacosamide is indicated to treat partial-onset seizures. It is also used with other medicines to treat primary generalized tonic-clonic seizures.
The company said it will manufacture the product at the group's formulation manufacturing facility in Moraiya, Ahmedabad.
As per IQVIA data, Lacosamide Tablets had annual sales of $249 million in the US.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
